Replimune Group (NASDAQ:REPL) Stock Price Up 9.6% – What’s Next?

Replimune Group, Inc. (NASDAQ:REPL)’s share price rose 9.6% during mid-day trading on Monday . The stock traded as high as $10.94 and last traded at $11.1710. 740,133 shares traded hands during mid-day trading, a decline of 84% from the average daily volume of 4,696,079 shares. The stock had previously closed at $10.19.

Wall Street Analyst Weigh In

Several equities analysts recently commented on REPL shares. Leerink Partners reiterated a “market perform” rating and set a $2.00 target price (down from $11.00) on shares of Replimune Group in a research note on Monday, April 13th. Wedbush lifted their target price on Replimune Group from $2.00 to $6.00 and gave the stock a “neutral” rating in a research report on Monday, June 1st. Jefferies Financial Group restated a “hold” rating and set a $2.00 price target (down from $13.00) on shares of Replimune Group in a research note on Monday, April 13th. BMO Capital Markets cut Replimune Group from a “market perform” rating to an “underperform” rating in a report on Monday, April 13th. Finally, HC Wainwright reaffirmed a “sell” rating on shares of Replimune Group in a report on Monday, April 13th. Seven investment analysts have rated the stock with a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Reduce” and a consensus price target of $4.88.

Replimune Group Stock Up 8.8%

The firm has a market capitalization of $915.29 million, a price-to-earnings ratio of -3.24 and a beta of 0.88. The firm has a fifty day moving average price of $5.43 and a 200 day moving average price of $7.25. The company has a current ratio of 5.60, a quick ratio of 5.60 and a debt-to-equity ratio of 0.33.

Insider Transactions at Replimune Group

In other Replimune Group news, insider Christopher Sarchi sold 12,000 shares of Replimune Group stock in a transaction on Monday, June 1st. The stock was sold at an average price of $9.24, for a total value of $110,880.00. Following the completion of the transaction, the insider owned 180,962 shares in the company, valued at approximately $1,672,088.88. The trade was a 6.22% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 5.20% of the company’s stock.

Institutional Trading of Replimune Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. International Assets Investment Management LLC bought a new position in shares of Replimune Group in the fourth quarter valued at about $29,000. CWM LLC grew its holdings in Replimune Group by 248.6% during the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after acquiring an additional 2,886 shares during the last quarter. Essential Partners LLC increased its position in Replimune Group by 562,400.0% in the 1st quarter. Essential Partners LLC now owns 5,625 shares of the company’s stock valued at $43,000 after acquiring an additional 5,624 shares in the last quarter. BNP Paribas Financial Markets increased its position in Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock valued at $64,000 after acquiring an additional 1,879 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in Replimune Group in the 2nd quarter valued at about $69,000. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.